[1]高红敏,杨红英,刘 鑫.血清中 microRNA-106b 对宫颈癌患者的早期诊断及预后预测价值[J].现代检验医学杂志,2020,35(06):85-86.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
 GAO Hong-min,YANG Hong-ying,LIU Xin.Value Analysis of Serum microRNA-106b in Early Diagnosis ofCervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(06):85-86.[doi:doi:10.3969/j.issn.1671-7414.2020.06.020]
点击复制

血清中 microRNA-106b 对宫颈癌患者的早期诊断及预后预测价值()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年06期
页码:
85-86
栏目:
论著
出版日期:
2020-12-30

文章信息/Info

Title:
Value Analysis of Serum microRNA-106b in Early Diagnosis ofCervical Cancer
文章编号:
1671-7414(2020)06-085-03
作者:
高红敏1 杨红英2 刘 鑫3
(1. 西安市第四医院妇产科,西安 710004; 2. 西安市第九医院妇产科,西安 710000;3. 西安大兴医院妇产科 , 西安 710014)
Author(s):
GAO Hong-min 1 YANG Hong-ying 2 LIU Xin 3
(1.Obstetrics and Gynecology Department, Xi’an Fourth Hospital,Xi’an 710004,China;2.Obstetrics and GynecologyDepartment, Xi’an Ninth Hospital, Xi’an 710004, China;3.Department of Obstetrics and Gynecology,Daxing Hospital, Xi’an 710014, China)
关键词:
宫颈癌microRNA-106b临床病理特征总体生存率
分类号:
R737.33;R730.43
DOI:
doi:10.3969/j.issn.1671-7414.2020.06.020
文献标志码:
A
摘要:
目的 探究宫颈癌(cervical cancer, CC)组织中microRNA-106b的表达与患者临床病理特征及总体生存率(overallsurvival,OS) 的关系。方法 选取 2017 年 9 月~ 2019 年 11 月西安市第四医院妇产科收治的经病理学确诊的 CC 患者150 例为研究对象,比较 microRNA-106b 在 CC 组织和癌旁正常组织中的相对表达量,并分析不同水平 microRNA-106b与 CC 患者临床病理特征和 OS 之间的关系。结果 microRNA-106b 在 CC 组织中的相对表达量为 0.075, 显著高于癌旁正常组织中的相对表达量 0.003 (P=0.0186)。不同水平 microRNA-106b 与 CC 患者的年龄、肿瘤直径、FIGO 分期无关 (P> 0.05),与淋巴结转移和分化程度有密切关系,差异有统计学意义 (χ 2 =13.95,7.21,P < 0.05)。microRNA-106b 高表达组患者的 OS 显著低于 microRNA-106b 低表达组,其差异具有统计学意义 (P=0.036)。结论 microRNA-106b 与 CC的发生、发展有密切关系,其对 CC 的诊治及预后有关键作用。

参考文献/References:

[1] HU Xiaoxia, SCHWARZ J K, LEWIS J S, et al. AmicroRNA expression signature for cervical cancerprognosis[J]. Cancer Research, 2010, 70(4):1441-1448.
[2] LI Shuang , HU Ting , L? Weiguo , et al. Changesin prevalence and clinical characteristics of cervicalcancer in the People’s Republic of China: a studyof 10 012 cases from anationwide working group[J].Oncologist, 2013, 18(10):1101-1107.
[3] TALICIA T. Cancer Facts & Figures 2012. AmericanCancer Society (ACS) [M]. Atlanta :GA AmericanCancer Society, 2012:66.
[4] MIRANDA K C,HUYNH T, TAY Y, et al. A pattern-based method for the identification of microRNAbinding sites and their corresponding heteroduplexes[J].Cell, 2006, 126(6):1203-1217.
[5] MITCHELL P S,PARKIN R K,KROH E M, et al.Circulating microRNAs as stable blood-based markersfor cancer detection[J]. Proc Natl Acad Sci USA, 2008,105(30):10513-10518.
[6] SCHWARZENBACH H, NISHIDA N,CALIN GA, et al. Clinical relevance of circulating cell-freemicroRNAs in cancer[J]. Nature Reviews ClinicalOncology, 2014, 11(Suppl 3):145-156.
[7] HAN Ying, LIU Mei, WANG Ziyi, et al. SerummicroRNAs related with chemoradiotherapy resistancein advanced-stage cervical squamous cell carcinoma [J].Translational Oncology,2017, 10(3):378-384.
[8] HOW C K,HOU S K,SHIH H C, et al. Expressionprofile of microRNAs in gram-negative bacterialsepsis[J]. Shock, 2015, 43(2):121-127.
[9] PARMIGIANI G, GARRETT E S,. IRIZARRY R A, etal. The analysis of gene expression data: an overviewof methods and software [M]. The Analysis of GeneExpression Data, New York: Springer,2003:1-45.
[10] SHIN J H, BLAY S , MCNENEY B,et al. LDheatmap:An R function for graphical display of pairwiselinkage disequilibria between single nucleotidepolymorphisms[J]. Journal of Statistical Software,2006, 16(3): 1-10.
[11] LI Feng,WANG Feiran,ZHU Changlai,et al. MiR-221 suppression through nanoparticle-based miRNAdelivery system for hepatocellular carcinoma therapyand its diagnosis as a potential biomarker[J]. Int JNanomedicine. 2018; 13: 2295–2307..
[12] LIEB V, WEIGELT K, SCHEINOST L, et al. Serumlevels of miR-320 family members are associated withclinical parameters and diagnosis in prostate cancerpatients.[J]. Oncotarget, 2018, 9(12):10402-10416.
[13] WANG Fengjun,ZHENG Zhiguo, GUO Jiangfeng, etal. Correlation and quantitation of microRNA aberrantexpression in tissues and sera from patients with breasttumor[J]. Gynecologic Oncology, 2010, 119(3): 586-593.
[14] GONG Chang, QU Shaohua, L? Xiaobin, et al.BRMS1L suppresses breast cancer metastasisby inducing epigenetic silence of FZD10 [J].NatCommun,2014, 5(50):591-602.
[15] GAO Chundi,ZHOU Chao,ZHUANG Jing ,et al.MicroRNA expression in cervical cancer: Noveldiagnostic and prognostic biomarkers.[J]. Journal ofcellular biochemistry, 2018, 119(8):7080-7090.
[16] 余小多 , 欧阳汉 , 林蒙 , 等 . 2009 年国际妇产科联盟子宫内膜癌分期标准对磁共振成像分期诊断价值的影响 [J]. 中华肿瘤杂志 , 2011,33 (9):692-696.YU Xiaoduo,OUYANG Han,LIN Meng,et al.Impact of2009 FIGO staging system on the diagnostic value ofpreoperative MRI staging of endometrial carcinoma[J].Chinese Journal of Oncology, 2011,33 (9):692-696.
[17] YI Yuexiong, LIU Yanyan , WU Wanrong ,et al.The role of miR-106p-5p in cervical cancer: fromexpression to molecular mechanism[J]. Cell DeathDiscovery, 2018, 4(1):87-108.
[18] CHENG Yuan,GUO Yanli, ZHANG Youyi,et al.MicroRNA-106b is involved in transforming growthfactor β1–induced cell migration by targetingdisabled homolog 2 in cervical carcinoma[J]. Journalof Experimental & Clinical Cancer Research, 2016,35(1):11.
[19] RUAN Tongde,GU Chuanlan , GUO Hongbo,et al.C-myc-regulated miR-106b promotes proliferation ofhuman bladder cancer cells by targeting DAPK2[J].International Journal of Clinical and ExperimentalPathology,2017,10(4), 4370-4376.

相似文献/References:

[1]田英,王双勇,赵雅,等.宫颈癌组织细胞中Numb基因表达及相关性研究[J].现代检验医学杂志,2015,30(06):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
 TIAN Ying,WANG Shuang-yong,ZHAO Ya,et al.Study on Correlation and Expression of Numb Gene in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2015,30(06):42.[doi:10.3969/j.issn.1671-7414.2015.06.012]
[2]顾益凤,朱自力,史跃燕,等.血浆硫氧还蛋白还原酶水平检测对宫颈癌早期诊断的价值研究[J].现代检验医学杂志,2019,34(02):40.[doi:10.3969/j.issn.1671-7414.2019.02.011]
 GU Yi-feng,ZHU Zi-li,SHI Yue-yan,et al.Study on the Value of Plasma Thioredoxin Reductase Levelin the Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):40.[doi:10.3969/j.issn.1671-7414.2019.02.011]
[3]陈 慎,杜明君,宋雅琴.宫颈组织HPV DNA与血清Chemerin,Leptin水平联合检测对宫颈癌早期诊断的价值分析[J].现代检验医学杂志,2019,34(03):42.[doi:10.3969/j.issn.1671-7414.2019.03.010]
 CHEN Shen,DU Ming-jun,SONG Ya-qin.Value of Combined Detection of HPV DNA and Serum Levelsof Chemerin and Leptin in Early Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2019,34(06):42.[doi:10.3969/j.issn.1671-7414.2019.03.010]
[4]周 静,李 智,周 玉,等.宫颈癌组织中 Ep-CAM和 Ki67的表达及临床意义[J].现代检验医学杂志,2019,34(06):24.[doi:10.3969 / j.issn.1671-7414.2019.06.006]
 ZHOU Jing,LI Zhi,ZHOU Yu,et al.Expression and Clinicd Value of Ep-CAM and Ki67 in the Cervial Carcinoma Tissue[J].Journal of Modern Laboratory Medicine,2019,34(06):24.[doi:10.3969 / j.issn.1671-7414.2019.06.006]
[5]徐晓锋a,王 纯b,卢国丰a,等.宫颈癌患者 Kruppel 样因子 6,p21 蛋白表达水平与病理特征及化疗敏感性的相关性分析[J].现代检验医学杂志,2020,35(06):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
 XU Xiao-feng a,WANG Chun b,LU Guo-feng a,et al.Correlation Analysis of KLF6 and p21 Protein Expression Levels andPathological Features and Chemotherapy Sensitivity in Patientswith Cervical Cancer[J].Journal of Modern Laboratory Medicine,2020,35(06):12.[doi:doi:10.3969/j.issn.1671-7414.2020.06.004]
[6]赵白信,于慧娟,焦方杰,等.经阴道彩色多普勒超声联合血清 miR-130a,miR-425-5p 水平检测对宫颈癌的诊断效能分析[J].现代检验医学杂志,2021,36(03):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
 ZHAO Bai-xin,YU Hui-juan,JIAO Fang-jie,et al.Analysis of Diagnostic Efficacy of Transvaginal Color Doppler UltrasoundCombined with Serum miR-130a and miR-425-5p Levels in Cervical Cancer[J].Journal of Modern Laboratory Medicine,2021,36(06):43.[doi:10.3969/j.issn.1671-7414.2021.03.010]
[7]张治洋,李功娟.10株宫颈癌细胞系中MALAT1的表达及其对顺铂敏感性的影响[J].现代检验医学杂志,2021,36(05):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
 ZHANG Zhi-yang,LI Gong-juan.Expression of MALAT1 in 10 Cervical Cancer Cell Lines and Its Effect onCisplatin Sensitivity[J].Journal of Modern Laboratory Medicine,2021,36(06):110.[doi:10.3969/j.issn.1671-7414.2021.05.024]
[8]郝艳芳,刘亚荣,黄玲玲,等.miRNA-195靶向调控 CCND2和 MYB抑制宫颈癌细胞增殖、迁移的机制研究[J].现代检验医学杂志,2022,37(01):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
 HAO Yan-fang,LIU Ya-rong,HUANG Ling-ling,et al.Study on the Mechanism of miRNA-195 Targeting CCND2 and MYB to Inhibit the Proliferation and Migration of Cervical Cancer Cells[J].Journal of Modern Laboratory Medicine,2022,37(06):130.[doi:10.3969/j.issn.1671-7414.2022.01.026]
[9]方 芳,吴 玲,魏善闯,等.宫颈癌患者血清LCN2水平表达与HPV病毒载量及临床分期的相关研究[J].现代检验医学杂志,2022,37(02):80.[doi:10.3969/j.issn.1671-7414.2022.02.017]
 FANG Fang,WU Ling,WEI Shan-chuang,et al.Correlation of Expression of Serum LCN2 Level with HPV Load and Clinical Stage in Patients with Cervical Cancer[J].Journal of Modern Laboratory Medicine,2022,37(06):80.[doi:10.3969/j.issn.1671-7414.2022.02.017]
[10]谌媛媛,李 静.宫颈脱落细胞中PAX1 和SOX1 基因甲基化对宫颈癌实验诊断的临床研究[J].现代检验医学杂志,2022,37(06):46.[doi:10.3969/j.issn.1671-7414.2022.06.009]
 CHEN Yuan-yuan,LI Jing.Clinical Study of PAX1 and SOX1 Gene Methylation in Cervical Exfoliated Cells for Experimental Diagnosis of Cervical Cancer[J].Journal of Modern Laboratory Medicine,2022,37(06):46.[doi:10.3969/j.issn.1671-7414.2022.06.009]

更新日期/Last Update: 2020-12-20